| scholarly article | Q13442814 |
| P50 | author | Huldrych F Günthard | Q40505165 |
| Deenan Pillay | Q57899870 | ||
| P2093 | author name string | Douglas D Richman | |
| Vincent Calvez | |||
| Roger Paredes | |||
| Victoria A Johnson | |||
| Robert Shafer | |||
| Annemarie M Wensing | |||
| P2860 | cites work | Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo | Q24535740 |
| Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine | Q28316118 | ||
| Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT) | Q28340342 | ||
| Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years | Q28379519 | ||
| Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria | Q33625367 | ||
| Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience | Q33649563 | ||
| Clinically relevant genotype interpretation of resistance to didanosine | Q33770146 | ||
| Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort | Q33910771 | ||
| Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy | Q33931265 | ||
| Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients | Q34112204 | ||
| Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics | Q34415921 | ||
| Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine | Q35122204 | ||
| Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro | Q36538644 | ||
| Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients | Q36870850 | ||
| Update of the drug resistance mutations in HIV-1: 2007. | Q36919747 | ||
| Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel | Q37189622 | ||
| Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways | Q37410667 | ||
| Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases | Q37489580 | ||
| Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy | Q39562375 | ||
| Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients | Q39606435 | ||
| Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort | Q39683582 | ||
| Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase | Q39737416 | ||
| Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity | Q40561855 | ||
| Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates | Q41902281 | ||
| Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease | Q42120771 | ||
| HIV-1 protease mutations and protease inhibitor cross-resistance | Q42421248 | ||
| Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score | Q42839647 | ||
| Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. | Q42844743 | ||
| HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy | Q42953782 | ||
| Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir | Q43057951 | ||
| Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa | Q43267414 | ||
| Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). | Q43280695 | ||
| Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. | Q43937808 | ||
| Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients | Q44004053 | ||
| Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. | Q44034071 | ||
| Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure | Q44118757 | ||
| The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis | Q44172310 | ||
| Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial | Q44252669 | ||
| Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs | Q44379153 | ||
| Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen | Q44405999 | ||
| Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial | Q44513458 | ||
| Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates | Q44598915 | ||
| Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir | Q44741225 | ||
| Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors | Q44811837 | ||
| Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens | Q44851489 | ||
| Genetic correlates of efavirenz hypersusceptibility | Q45021997 | ||
| Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial | Q45270627 | ||
| Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group | Q45743779 | ||
| Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients | Q46160845 | ||
| Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection | Q46466415 | ||
| Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy | Q46807875 | ||
| Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. | Q50971561 | ||
| Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. | Q51547763 | ||
| Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. | Q54585505 | ||
| Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level | Q80082544 | ||
| Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine | Q80713101 | ||
| Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis | Q82428879 | ||
| Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors | Q83128879 | ||
| P433 | issue | 4 | |
| P921 | main subject | HIV | Q15787 |
| P304 | page(s) | 156-164 | |
| P577 | publication date | 2011-11-01 | |
| P1433 | published in | Topics in antiviral medicine | Q26841872 |
| P1476 | title | 2011 update of the drug resistance mutations in HIV-1 | |
| P478 | volume | 19 |
| Q33664179 | A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002-2011 |
| Q27683249 | A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase |
| Q44536459 | A novel view of modelling interactions between synthetic and biological polymers via docking |
| Q28533996 | A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity |
| Q34352429 | APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model |
| Q34998736 | Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. |
| Q39178072 | Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors |
| Q28534423 | Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study |
| Q36896555 | Antiretroviral Stewardship in a Pediatric HIV Clinic: Development, Implementation and Improved Clinical Outcomes |
| Q64890039 | Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam. |
| Q36419479 | Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda |
| Q37577550 | Antiretroviral treatment interruptions induced by the Kenyan postelection crisis are associated with virological failure |
| Q36276790 | Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors |
| Q34528801 | Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis |
| Q34493132 | Automated analysis of phylogenetic clusters |
| Q41812289 | Baseline-transmitted V106V/I/M non-nucleoside reverse transcriptase inhibitor resistance in HIV-1 subtype B infection. |
| Q37263786 | Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase |
| Q33988153 | Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis |
| Q27672873 | Capturing the Reaction Pathway in Near-Atomic-Resolution Crystal Structures of HIV-1 Protease |
| Q36292765 | Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns |
| Q37026564 | Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy |
| Q36760224 | Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agents |
| Q38111393 | Computer-Aided Approaches for Targeting HIVgp41. |
| Q34112568 | Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations |
| Q36372693 | Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity |
| Q36414604 | Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. |
| Q39511996 | Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future |
| Q26852626 | Current perspectives on HIV-1 antiretroviral drug resistance |
| Q28535401 | DB-02, a C-6-cyclohexylmethyl substituted pyrimidinone HIV-1 reverse transcriptase inhibitor with nanomolar activity, displays an improved sensitivity against K103N or Y181C than S-DABOs |
| Q30887525 | Data-intensive analysis of HIV mutations |
| Q28533216 | Description of HIV-1 group M molecular epidemiology and drug resistance prevalence in Equatorial Guinea from migrants in Spain |
| Q34563005 | Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes |
| Q36817632 | Detection of HIV-1 minority variants containing the K103N drug-resistance mutation using a simple method to amplify RNA targets (SMART). |
| Q55511989 | Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy. |
| Q37025712 | Differential impact of resistance-associated mutations to protease inhibitors and nonnucleoside reverse transcriptase inhibitors on HIV-1 replication capacity |
| Q28484213 | Differential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and C |
| Q37107955 | Drug-resistant tuberculosis treatment complicated by antiretroviral resistance in HIV coinfected patients: a report of six cases in Lesotho |
| Q89366334 | Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an |
| Q36969977 | Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine |
| Q36156679 | Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment |
| Q35536368 | Epistasis as a determinant of the HIV-1 protease's robustness to mutation |
| Q34288751 | Estimating the fitness cost of escape from HLA presentation in HIV-1 protease and reverse transcriptase. |
| Q28542508 | Estimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany |
| Q36902291 | Evaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy in India |
| Q36667504 | Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory |
| Q28543688 | Evaluation of dried blood spots collected on filter papers from three manufacturers stored at ambient temperature for application in HIV-1 drug resistance monitoring |
| Q37664254 | Evaluation of longitudinal clinical outcomes and adherence to care among HIV-infected refugees |
| Q26862297 | Evolutionary rescue: linking theory for conservation and medicine |
| Q36937877 | Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-line antiretroviral therapy by WHO 2010 guidelines |
| Q36558961 | Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country |
| Q40838288 | Fluorometric assay for phenotypic differentiation of drug-resistant HIV mutants. |
| Q36379570 | Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors |
| Q36790317 | Genetic Analysis of HIV-1 Integrase Sequences from Treatment Naive Individuals in Northeastern South Africa |
| Q35942373 | Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients |
| Q28550283 | HIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, China |
| Q26864534 | HIV Drug Resistance: Problems and Perspectives |
| Q28534576 | HIV behind bars: human immunodeficiency virus cluster analysis and drug resistance in a reference correctional unit from southern Brazil |
| Q34549498 | HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya |
| Q34649651 | HIV restriction by APOBEC3 in humanized mice |
| Q36369628 | HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients |
| Q28535421 | HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana. |
| Q28540536 | HIV-1 pol diversity among female bar and hotel workers in Northern Tanzania |
| Q33900459 | HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. |
| Q28484394 | High drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in Spain |
| Q28543358 | High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa |
| Q34484449 | High viremia and low level of transmitted drug resistance in anti-retroviral therapy-naïve perinatally-infected children and adolescents with HIV-1 subtype C infection |
| Q28538692 | High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen |
| Q36639618 | Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals |
| Q64100582 | Human Immunodeficiency Virus-1 Diversity in the Moscow Region, Russia: Phylodynamics of the Most Common Subtypes |
| Q40440258 | Identification of Novel Resistance-Related Polymorphisms in HIV-1 Subtype C RT Connection and RNase H Domains from Patients Under Virological Failure in Brazil |
| Q28537991 | Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strains |
| Q37644009 | Identifying recombination hot spots in the HIV-1 genome |
| Q43760953 | Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy |
| Q35540712 | Impact of M36I polymorphism on the interaction of HIV-1 protease with its substrates: insights from molecular dynamics |
| Q28486262 | In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis |
| Q33589204 | In vivo mutation rates and the landscape of fitness costs of HIV-1. |
| Q36559597 | Inefficient vaginal transmission of tenofovir-resistant HIV-1 |
| Q36184643 | Intermittent HIV-1 viremia (blips) and virological failure in a cohort of people living with HIV from São Paulo, Brazil |
| Q28485321 | Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens |
| Q28485373 | Long-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort study |
| Q37169938 | Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study |
| Q36386787 | Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis |
| Q37582339 | Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP. |
| Q36162047 | Mechanism of dissociative inhibition of HIV protease and its autoprocessing from a precursor |
| Q37247492 | Molecular mechanisms of HIV type 1 prophylaxis failure revealed by single-genome sequencing |
| Q35237575 | Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. |
| Q36826639 | Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping |
| Q41140055 | Natural Plant Alkaloid (Emetine) Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity. |
| Q51039642 | Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals. |
| Q36250362 | No increase of drug-resistant HIV type 1 prevalence among drug-naive individuals in Northern Vietnam |
| Q27675818 | Novel P2 Tris-tetrahydrofuran Group in Antiviral Compound 1 (GRL-0519) Fills the S2 Binding Pocket of Selected Mutants of HIV-1 Protease |
| Q47396961 | PHYLOSCANNER: Inferring Transmission from Within- and Between-Host Pathogen Genetic Diversity. |
| Q64242149 | Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens |
| Q41494718 | Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients |
| Q30670919 | Phylogenetic Investigation of a Statewide HIV-1 Epidemic Reveals Ongoing and Active Transmission Networks Among Men Who Have Sex With Men. |
| Q34289476 | Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia |
| Q40432241 | Physiological Mg2+ Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro. |
| Q37029110 | Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children |
| Q34981322 | Potential elucidation of a novel CTL epitope in HIV-1 protease by the protease inhibitor resistance mutation L90M. |
| Q35588149 | Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial |
| Q28539186 | Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure |
| Q37617604 | Prevalence and outcomes of recycling NNRTIs despite documented NNRTI resistance in HIV-infected children and youth |
| Q28486583 | Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011 |
| Q28484064 | Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencing |
| Q41844750 | Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process |
| Q36593975 | Pulsed EPR characterization of HIV-1 protease conformational sampling and inhibitor-induced population shifts |
| Q36718188 | Rapid deep sequencing of patient-derived HIV with ion semiconductor technology. |
| Q28488527 | Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice |
| Q28539563 | Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution |
| Q34420782 | Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients. |
| Q33714130 | Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa |
| Q26796151 | Respiratory virus modulation of host nucleocytoplasmic transport; target for therapeutic intervention? |
| Q42159090 | Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S. |
| Q37083647 | Rilpivirine resistance-associated mutations among antiretroviral-naive patients infected with HIV-1 in Asia |
| Q34650691 | Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set |
| Q28485108 | Screening for and verification of novel mutations associated with drug resistance in the HIV type 1 subtype B(') in China |
| Q37036823 | Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitors |
| Q33622927 | Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism. |
| Q28486299 | Significantly improved HIV inhibitor efficacy prediction employing proteochemometric models generated from antivirogram data |
| Q35642600 | Small molecule inhibitors of HIVgp41 N-heptad repeat trimer formation |
| Q90449749 | Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease |
| Q40180218 | Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimer. |
| Q36172087 | Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase |
| Q35073452 | Targeting RNA-protein interactions within the human immunodeficiency virus type 1 lifecycle |
| Q38400338 | Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy |
| Q28539260 | The HIVToolbox 2 web system integrates sequence, structure, function and mutation analysis |
| Q37288671 | The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance |
| Q38262356 | The lysine 65 residue in HIV-1 reverse transcriptase function and in nucleoside analog drug resistance |
| Q36772619 | The role of etravirine in the management of treatment-experienced pediatric patients with HIV. |
| Q36582418 | Transmitted Drug Resistance among People Living with HIV/Aids at Major Cities of Sao Paulo State, Brazil |
| Q42549313 | Transmitted HIV resistance among pregnant young women infected with HIV-1 in Brazil |
| Q28488769 | Trends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011 |
| Q34702301 | Trends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010 |
| Q43778057 | Update of the drug resistance mutations in HIV-1: March 2013. |
| Q33717011 | Using HIV networks to inform real time prevention interventions |
| Q30830042 | Viral and Host Characteristics of Recent and Established HIV-1 Infections in Kisumu based on a Multiassay Approach |
| Q33788085 | Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe |
| Q37582314 | Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch |
| Q33624953 | Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis |
| Q34523909 | Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda |
Search more.